Lisinopril (Page 6 of 6)
16 HOW SUPPLIED/STORAGE AND HANDLING
Lisinopril Tablets, USP 40 mg are supplied as follows:
40 mg Tablets: Yellow, round, unscored, flat-faced, beveled-edge tablets, debossed “ WATSON ” and “ 409 ” on the periphery of one side and plain on the other side, in bottles of 90 NDC 51655-292-26 and in bottles of 30 NDC 51655-292-52
Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container as defined in the USP.
17 PATIENT COUNSELING INFORMATION
NOTE: This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations ( 8.1)].
Angioedema: Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including lisinopril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
Lactation: Advise women not to breastfeed during treatment with lisinopril [see Use in Specific Populations ( 8.2)].
Symptomatic Hypotension: Tell patients to report light-headedness especially during the first few days of therapy. If actual syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physician.
Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; advise patients accordingly.
Hyperkalemia: Tell patients not to use salt substitutes containing potassium without consulting their physician. Hypoglycemia: Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for hypoglycemia closely, especially during the first month of combined use [see Drug Interactions ( 7.2)].
Leukopenia/Neutropenia: Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of leukopenia/neutropenia.
Brands listed are trademarks of their respective owners.
Manufactured by:
Watson Pharma Private Limited
Verna, Salcette Goa 403 722 INDIA
Distributed by:
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Revised: November 2017
Principal Display Panel
NDC: 51655-292-26
| LISINOPRIL lisinopril tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| Labeler — Northwind Pharmaceuticals (036986393) |
| Registrant — Northwind Pharmaceuticals (036986393) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Northwind Pharmaceuticals | 036986393 | repack (51655-292) | |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| EPM Packaging Inc. | 079124340 | repack (51655-292) | |
Revised: 12/2021 Northwind Pharmaceuticals
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.